Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “PI3K Gene Mutation”

75 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 75 results

Large-scale testing (Phase 3)UnknownNCT06249997
What this trial is testing

An Open-Label Study to Assess the Safety & Efficacy of Leniolisib in Japanese Patients With APDS

Who this might be right for
APDS Gene Mutation
Pharming Technologies B.V. 3
Not applicableLooking for participantsNCT06805812
What this trial is testing

Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study

Who this might be right for
Breast AdenocarcinomaBreast Cancer Stage IVBreast Cancer, Metastatic+38 more
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 3,500
Early research (Phase 1)Study completedNCT02260661
What this trial is testing

Phase I, Dose Study to Look at the Safety and Pharmacokinetics of AZD8835 in Patients With Advanced Solid Tumours

Who this might be right for
Advanced Solid MalignanciesBreast Cancer - ER+, HER2 -Breast Cancer - ER+, HER2-, PIK3CA Gene Mutation
AstraZeneca 20
Early research (Phase 1)Study completedNCT01449058
What this trial is testing

A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors

Who this might be right for
Advanced and Selected Solid TumorsAMLHigh Risk and Very High Risk MDS
Array BioPharma 139
Testing effectiveness (Phase 2)Looking for participantsNCT05768139
What this trial is testing

First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

Who this might be right for
Breast CancerSolid Tumors, Adult
Eli Lilly and Company 720
Testing effectiveness (Phase 2)Active Not RecruitingNCT04439175
What this trial is testing

Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell Neoplasm+3 more
National Cancer Institute (NCI) 70
Not applicableEnded earlyNCT05571670
What this trial is testing

Bile Acids in Acute Insulin Resistance

Who this might be right for
PI3K Gene MutationAKT Gene MutationMTOR Gene Mutation+2 more
Columbia University 3
Testing effectiveness (Phase 2)Study completedNCT02451956
What this trial is testing

Study of AZD5363 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring PIK3CA Mutation and/or PIK3CA Amplification as a Second-line Chemotherapy

Who this might be right for
Advanced Gastric Cancer
Samsung Medical Center 21
Not applicableEnrolling By InvitationNCT06943313
What this trial is testing

Breast Cancer PET/CT Imaging With 68Ga-pAKTi

Who this might be right for
Breast CancersPIK3CA Mutation-Related TumorsPI3K Pathway Activated Tumors+1 more
Fudan University 20
Testing effectiveness (Phase 2)Ended earlyNCT02644122
What this trial is testing

SF1126 in Recurrent or Progressive SCCHN and Mutations in PIK3CA Gene and/or PI-3 Kinase Pathway Genes

Who this might be right for
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma
Ezra Cohen 1
Large-scale testing (Phase 3)Study completedNCT03285802
What this trial is testing

Treatment Plan for an Individual Patient With Recurrent Uterine Papillary Serous Carcinoma (UPSC) With PIK3CA Gene Mutation

Who this might be right for
Uterine Cancer
Greater Baltimore Medical Center 1
Early research (Phase 1)Ended earlyNCT02476955
What this trial is testing

Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole

Who this might be right for
Solid TumorsOvarian CancerEndometrial Cancer
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) 41
Large-scale testing (Phase 3)Active Not RecruitingNCT04208178
What this trial is testing

Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation

Who this might be right for
Advanced HER2+Breast Cancer
Novartis Pharmaceuticals 19
Testing effectiveness (Phase 2)Temporarily pausedNCT03994796
What this trial is testing

Genetic Testing in Guiding Treatment for Patients With Brain Metastases

Who this might be right for
CDK Gene MutationMetastatic Malignant Neoplasm in the BrainMetastatic Malignant Solid Neoplasm+4 more
Alliance for Clinical Trials in Oncology 186
Early research (Phase 1)Not Yet RecruitingNCT07383506
What this trial is testing

Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors

Who this might be right for
PIK3CA MutationsAdvanced Solid Tumors, AdultEndometrial Cancer+2 more
Cogent Biosciences, Inc. 90
Early research (Phase 1)Study completedNCT05759949
What this trial is testing

First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors

Who this might be right for
PIK3CA MutationSolid Tumor, AdultHER2-negative Breast Cancer+5 more
Relay Therapeutics, Inc. 41
Large-scale testing (Phase 3)Active Not RecruitingNCT05038735
What this trial is testing

Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 212
Testing effectiveness (Phase 2)Looking for participantsNCT06789913
What this trial is testing

Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation

Who this might be right for
PIK3CA-Related Overgrowth Spectrum (PROS)Lymphatic MalformationsVascular Malformations+4 more
Relay Therapeutics, Inc. 277
Not applicableStudy completedNCT05054166
What this trial is testing

Efficacy of Everolimus-containing Chemotherapy in HER2- mBC Patients With PI3K/AKT/mTOR Mutations Study

Who this might be right for
Breast CancerPI3K/AKT/mTOR Pathway MutationEverolimus
Zhejiang Cancer Hospital 14
Early research (Phase 1)Study completedNCT01613950
What this trial is testing

PI3K Inhibitor BYL719 in Combination With the HSP90 Inhibitor AUY922 in Patients With Advanced or Metastatic Gastric Cancer

Who this might be right for
Stomach Neoplasms Esophageal Neoplasms Metastatic Gastric Cancer Mutated PI3KCA Protein Overexpressed HER2 Protein
Novartis Pharmaceuticals 18
Load More Results